BackgroundOxidative stress is implicated in the pathogenesis of migraine, but no published studies have examined both oxidative stress levels and oxidative DNA damage on the same patient group.MethodsIn this study, total oxidant status (TOS); total antioxidant status (TAS); oxidative stress index (OSI); and 8-hydroxy-2′-deoxyguanosine (8-OHdG), which is an indicator of oxidative DNA damage, were measured in the plasma samples of 50 prophylactic unmediated migraineurs (11 with aura and 39 without aura) and 30 matched healthy volunteers.ResultsNo significant differences in TAS, TOS, and OSI values were observed between patients and controls. However, plasma 8-OHdG levels were found to be significantly higher in migraine patients than in the control group (p = 0.001); this increase in plasma 8-OHdG levels was more prominent in cases with migraine without aura than with aura (p = 0.001). Our results suggested an evidence of oxidative stress-related DNA damage in migraine.ConclusionDNA damage reflected by plasma 8-OHdG did not studied in migraine before. Therefore, further research on oxidative stress-related DNA damage and the extent of its clinical manifestations in migraine may provide additional data to our current knowledge.

No abstract

No abstract

Parkinson's disease (PD) is a frequently occurring neurodegenerative motor disorder adversely impacting global health. There is a paucity of biomarkers and diagnostics that can forecast susceptibility to PD. A new research frontier for PD pathophysiology is the study of variations in microRNA (miRNA) expression whereby miRNAs serve as "upstream regulators" of gene expression in relation to functioning of the dopamine neuronal pathways. Leucine-Rich Repeat Kinase 2 (LRRK2) is a frequently studied gene in PD. Little is known about the ways in which expression of miRNAs targeting LRKK2 impact PD susceptibility. In a sample of 204 unrelated subjects (102 persons with PD and 102 healthy controls), we report here candidate miRNA expression in whole blood samples as measured by real-time PCR (hsa-miR-4671-3p, hsa-miR-335-3p, hsa-miR-561-3p, hsa-miR-579-3p, and hsa-miR-3143) that target LRRK2. Using step-wise logistic regression, and controlling for covariates such as age, gender, PD disease severity, concomitant medications, and co-morbidity, we found that the combination of has-miR-335-3p, has-miR-561-3p, and has-miR-579-3p account for 50% of the variation in regards to PD susceptibility (p<0.0001). Notably, the hsa-miR-561-3p expression was the most robust predictor of PD in both univariate and multivariate analyses (p<0.001). Moreover, the biological direction (polarity) of the association was plausible in that the candidate miRNAs displayed a diminished expression in patients. This is consistent with the hypothesis that decreased levels of miRNAs targeting LRRK2 might result in a gain of function for LRRK2, and by extension, loss of neuronal viability. To the best of our knowledge, this is the first clinical association study of the above candidate miRNAs' expression in PD using peripheral samples. These observations may guide future clinical diagnostics research on PD.

Children should be individualized for the treatment of TCS. Each patient must be evaluated neurologically and radiologically for the accurate diagnosis. Surgical untethering is the safe and effective method of treatment for children with TCS.